Clinical Evaluation of Aromatic Wentong in the Treatment of Coronary Microvascular Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

528

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Coronary Microvascular Disease
Interventions
DRUG

Kuangxiong Aerosol

Patients in the intervention group will receive Kuangxiong Aerosol for eight weeks, in addition to guideline-recommended medications. The aerosol will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.

DRUG

Placebo Drug

Patients in the control group will receive a placebo version of Kuangxiong Aerosol for eight weeks, alongside guideline-recommended medications. The placebo will be administered sublingually (under the tongue), with a dosage of two sprays per dose, three times daily.

Trial Locations (1)

100029

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

China-Japan Friendship Hospital

OTHER